Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59

22 Jun 2005

Abstract excerpt

Expression of the complement-regulatory proteins (CRP) CD46, CD55 and CD59 represents a strategy used by tumor cells to evade complement-dependent cell cytoxicity stimulated by monoclonal antibodies. We have isolated two single-chain variable fragments (scFv) to CD55 and CD59 from a human phage-display library and from these scFv we have produced two miniantibodies (MB), MB-55 (against CD55) and MB-59 (against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement system in diseases
Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 15971270
DOI: 10.1002/eji.200425920

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59PMID 15971270Read ↗

Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancerSemantic proximity Read ↗

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.Semantic proximity Read ↗

Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector MechanismsSemantic proximity Read ↗

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomasSemantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodiesSemantic proximity Read ↗

IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodiesSemantic proximity Read ↗

Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapySemantic proximity Read ↗

Complement as a Biological Tool to Control Tumor GrowthSemantic proximity Read ↗

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer PatientsSemantic proximity Read ↗

Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.Semantic proximity Read ↗

Isotype selection for antibody-based cancer therapySemantic proximity Read ↗

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burdenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.